

# Matthias Cavassini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628385/publications.pdf>

Version: 2024-02-01

414  
papers

17,642  
citations

13099

68  
h-index

22166

113  
g-index

434  
all docs

434  
docs citations

434  
times ranked

17400  
citing authors

#	ARTICLE	IF	CITATIONS
1	EBV-positive large B-cell lymphoma with an unusual intravascular presentation and associated haemophagocytic syndrome in an HIV-positive patient: report of a case expanding the spectrum of EBV-positive immunodeficiency-associated lymphoproliferative disorders. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 699-705.	2.8	3
2	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 306-316.	4.0	5
3	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	5.8	3
4	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e1-611.e7.	6.0	3
5	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	3.0	47
6	HIV testing in termination of pregnancy and colposcopy services: a scoping review. <i>Sexually Transmitted Infections</i> , 2022, 98, 143-149.	1.9	4
7	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	1.9	69
8	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	3.0	7
9	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	4.0	4
10	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	4.0	3
11	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	3.3	27
12	A highly virulent variant of HIV-1 circulating in the Netherlands. <i>Science</i> , 2022, 375, 540-545.	12.6	39
13	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	4.0	3
14	Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). <i>HIV Medicine</i> , 2022, 23, 417-425.	2.2	6
15	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	2.1	0
16	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
17	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 689-699.	1.8	12
18	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	3

#	ARTICLE	IF	CITATIONS
19	Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. <i>Lancet HIV</i> , 2022, 9, e404-e413.	4.7	10
20	Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. <i>PLoS Pathogens</i> , 2022, 18, e1010673.	4.7	4
21	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	3.5	4
22	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021, 73, e2134-e2141.	5.8	23
23	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	5.8	9
24	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	5.8	10
25	Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 530-536.	1.2	12
26	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1413-1421.	5.8	2
27	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	2.2	6
28	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	3.5	4
29	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	1.9	2
30	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. <i>Nature Communications</i> , 2021, 12, 1219.	12.8	2
31	The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. <i>International Journal of STD and AIDS</i> , 2021, 32, 729-739.	1.1	5
32	The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108481.	3.2	13
33	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.	3.3	8
34	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	3.9	66
35	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0246579.	2.5	3
36	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	2.4	0

#	ARTICLE	IF	CITATIONS
37	Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2021, 22, 623-628.	2.2	2
38	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. <i>ELife</i> , 2021, 10, .	6.0	3
39	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	5.8	5
40	Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab316.	0.9	18
41	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	2.2	6
42	Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial. <i>Journal of Infection</i> , 2021, 83, 354-360.	3.3	7
43	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab032.	0.9	16
44	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, 73, 2361-2364.	5.8	1
45	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	3.0	14
46	Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial. <i>Aids</i> , 2021, 35, 619-624.	2.2	3
47	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. <i>Trials</i> , 2021, 22, 724.	1.6	9
48	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Heart Journal</i> , 2021, 42, .	2.2	1
49	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	3.2	6
50	Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. <i>HIV Medicine</i> , 2021, 22, 346-359.	2.2	2
51	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020, 70, 297-303.	5.8	10
52	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 637-644.	5.8	3
53	The Neurocognitive Assessment in the Metabolic and Aging Cohort (<sc>NAMACO</sc>) study: baseline participant profile. <i>HIV Medicine</i> , 2020, 21, 30-42.	2.2	24
54	How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?. <i>HIV Medicine</i> , 2020, 21, 342-348.	2.2	14

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	2.2	18
56	Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. <i>HIV Medicine</i> , 2020, 21, 228-239.	2.2	46
57	An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa323.	0.9	5
58	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 517-524.	2.1	7
59	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.	4.0	7
60	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. <i>Viruses</i> , 2020, 12, 1241.	3.3	3
61	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	12.8	5
62	Authors'™ reply to A. Winston, A. Cotter, M. Gisslen, P. W. G. Mallon and P. Cinque. <i>HIV Medicine</i> , 2020, 21, e19-e20.	2.2	1
63	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	4.0	5
64	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	4.0	22
65	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegrovir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	1.6	22
66	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa019.	0.9	18
67	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.9	7
68	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020, 146, 3134-3146.	5.1	14
69	Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 655-660.	4.0	24
70	Real-life management of drug-drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1972-1980.	3.0	8
71	Aging does not impact drug-drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020, 34, 949-952.	2.2	2
72	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	3.5	5

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™HIV trial. PLoS Medicine, 2020, 17, e1003421.	8.4	23
74	Epidemiology of sexually transmitted infections among female sex workers in Switzerland: a local, exploratory, cross-sectional study. Swiss Medical Weekly, 2020, 150, w20357.	1.6	4
75	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. Antiviral Therapy, 2020, 25, 43-54.	1.0	2
76	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infectious Diseases, 2020, 7, ofaa470.	0.9	1
77	Title is missing!., 2020, 17, e1003421.		0
78	Title is missing!., 2020, 17, e1003421.		0
79	Title is missing!., 2020, 17, e1003421.		0
80	Title is missing!., 2020, 17, e1003421.		0
81	Title is missing!., 2020, 17, e1003421.		0
82	Title is missing!., 2020, 17, e1003421.		0
83	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2019, 68, 827-833.	5.8	7
84	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virusâ€“coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	5.8	30
85	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121733.	2.3	10
86	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.9	28
87	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
88	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. PLoS Pathogens, 2019, 15, e1007918.	4.7	16
89	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€“2017. Journal of the International AIDS Society, 2019, 22, e25339.	3.0	24
90	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infectious Diseases, 2019, 19, 834.	2.9	6

#	ARTICLE	IF	CITATIONS
91	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697.	3.0	23
92	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	2.4	7
93	Why do sub-Saharan Africans present late for HIV care in Switzerland?. <i>HIV Medicine</i> , 2019, 20, 418-423.	2.2	8
94	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2468-2470.	3.0	3
95	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2019, 24, 343-353.	1.0	4
96	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253.	4.0	6
97	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265.	4.0	27
98	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.	5.8	11
99	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897.	5.8	7
100	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. <i>Journal of Infectious Diseases</i> , 2019, 220, 91-99.	4.0	24
101	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.9	38
102	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019, 33, 1719-1727.	2.2	9
103	Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. <i>Aids</i> , 2019, 33, S271-S281.	2.2	5
104	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 292-300.	2.1	24
105	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 508-515.	2.1	0
106	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 468-472.	3.0	9
107	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz277.	0.9	20
108	Imaging patterns of <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive and renal transplant patients - a multicentre study. <i>Swiss Medical Weekly</i> , 2019, 149, w20130.	1.6	5



#	ARTICLE	IF	CITATIONS
109	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 735-742.	5.8	37
110	Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2018, 19, 420-425.	2.2	12
111	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	2.2	4
112	Neglect of attention to reproductive health in women with <scp>HIV</scp> infection: contraceptive use and unintended pregnancies in the Swiss <scp>HIV</scp> Cohort Study. <i>HIV Medicine</i> , 2018, 19, 339-346.	2.2	9
113	Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study. <i>Journal of Biomedical Informatics</i> , 2018, 79, 1-6.	4.3	5
114	Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells. <i>Cell Reports</i> , 2018, 23, 942-950.	6.4	89
115	Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy067.	0.9	12
116	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. <i>Clinical Infectious Diseases</i> , 2018, 66, 1099-1108.	5.8	24
117	No Effect of Pegylated Interferon- $\alpha$ on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1883-1888.	4.0	10
118	A prospective multicentre study of healthcare provider preference in rapid HIV testing kits: Determine versus INSTI. <i>International Journal of STD and AIDS</i> , 2018, 29, 51-56.	1.1	1
119	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	2.2	5
120	<scp>HIV</scp>-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy. <i>HIV Medicine</i> , 2018, 19, 49-58.	2.2	21
121	Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. <i>BMJ Open</i> , 2018, 8, e021203.	1.9	0
122	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	4.9	17
123	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018, 32, 2759-2765.	2.2	6
124	Non-targeted HIV testing in the emergency department: not just <i>how</i> but <i>where</i>. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 893-905.	4.4	4
125	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	8.9	37
126	Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy084.	0.9	3



#	ARTICLE	IF	CITATIONS
127	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	27.8	47
128	Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals. <i>Frontiers in Immunology</i> , 2018, 9, 144.	4.8	48
129	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.9	8
130	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	8.5	29
131	Content analysis of antiretroviral adherence enhancing interview reports. <i>Patient Education and Counseling</i> , 2018, 101, 1676-1682.	2.2	7
132	Missed opportunities for HIV testing among patients newly presenting for HIV care at a Swiss university hospital: a retrospective analysis. <i>BMJ Open</i> , 2018, 8, e019806.	1.9	19
133	Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. <i>HIV Medicine</i> , 2018, 19, 688-697.	2.2	6
134	Molecular characterization of <i>Treponema pallidum</i> subsp. <i>pallidum</i> in Switzerland and France with a new multilocus sequence typing scheme. <i>PLoS ONE</i> , 2018, 13, e0200773.	2.5	55
135	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.9	17
136	CD32 and PD-1 Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. <i>Journal of Virology</i> , 2018, 92, .	3.4	38
137	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
138	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	2.2	14
139	Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: A randomized controlled study. <i>PLoS ONE</i> , 2018, 13, e0190767.	2.5	16
140	HIV and Aging – Perhaps Not as Dramatic as We Feared?. <i>Gerontology</i> , 2018, 64, 446-456.	2.8	7
141	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. <i>Journal of Infection</i> , 2018, 76, 186-195.	3.3	12
142	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.	5.8	34
143	High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1056-1061.	1.2	9
144	Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2017, 18, 564-572.	2.2	4

#	ARTICLE	IF	CITATIONS
145	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV</i> , 2017, 4, e349-e356.	4.7	805
146	Mining for pairs: shared clinic visit dates identify steady <scp>HIV</scp>-positive partnerships. <i>HIV Medicine</i> , 2017, 18, 667-676.	2.2	2
147	Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. <i>Aids</i> , 2017, 31, 1859-1866.	2.2	15
148	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	5.8	23
149	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	4.7	31
150	Human papillomavirus antibody response following HAART initiation among MSM. <i>Aids</i> , 2017, 31, 561-569.	2.2	11
151	Rivastigmine decreases brain damage in <scp>HIV</scp> patients with mild cognitive deficits. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 915-920.	3.7	1
152	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	5.8	75
153	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	32
154	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	3.7	101
155	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.	0.9	10
156	The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx070.	0.9	34
157	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	6.0	16
158	Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study. <i>PLoS ONE</i> , 2017, 12, e0180389.	2.5	14
159	Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 476.	2.9	8
160	Life expectancy in HIV-positive persons in Switzerland. <i>Aids</i> , 2017, 31, 427-436.	2.2	193
161	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
162	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 506-515.	2.0	2

#	ARTICLE	IF	CITATIONS
163	Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. HIV Medicine, 2016, 17, 280-288.	2.2	14
164	Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest Switzerland. Sexually Transmitted Diseases, 2016, 43, 44-48.	1.7	6
165	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Scientific Reports, 2016, 6, 27580.	3.3	15
166	Association of disclosure of HIV status with medication adherence. Patient Education and Counseling, 2016, 99, 1413-1420.	2.2	17
167	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	3.0	13
168	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.9	20
169	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
170	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genetics in Medicine, 2016, 18, 814-822.	2.4	36
171	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2016, 214, 399-402.	4.0	47
172	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	30.7	133
173	Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. Oncologist, 2016, 21, 1176-1182.	3.7	7
174	Interventions to improve adherence to drug treatment. , 2016, , 381-391.		0
175	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. International Journal of Infectious Diseases, 2016, 51, 97-102.	3.3	18
176	Development of an algorithm for analysing the electronic measurement of medication adherence in routine HIV care. International Journal of Clinical Pharmacy, 2016, 38, 1210-1218.	2.1	13
177	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (United States), 2016, 95, e5094.	1.0	22
178	Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management. HIV Medicine, 2016, 17, 390-396.	2.2	3
179	Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2016, 3, ofw101.	0.9	5
180	PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nature Medicine, 2016, 22, 754-761.	30.7	388

#	ARTICLE	IF	CITATIONS
181	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016, 214, 599-606.	4.0	34
182	In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. <i>Journal of Virology</i> , 2016, 90, 1858-1871.	3.4	30
183	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw022.	0.9	15
184	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
185	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	5.8	52
186	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	5.8	60
187	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 43-52.	9.1	256
188	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	2.5	86
189	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016, 146, w14348.	1.6	31
190	Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015, 20, 165-175.	1.0	41
191	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	1.0	5
192	Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	3.4	5
193	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.9	38
194	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 413-421.	2.1	67
195	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	2.2	5
196	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	2.2	72
197	Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. <i>Aids</i> , 2015, 29, 373-383.	2.2	87
198	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.9	20

#	ARTICLE	IF	CITATIONS
199	Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2015, 2, ofv077-ofv077.	0.9	35
200	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. Drug Metabolism and Disposition, 2015, 44, 151-161.	3.3	27
201	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infectious Diseases, 2015, 15, 382.	2.9	29
202	Cryptococcus neoformans meningitis with negative cryptococcal antigen: Evaluation of a new immunochromatographic detection assay. New Microbes and New Infections, 2015, 4, 1-4.	1.6	13
203	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. Journal of Infectious Diseases, 2015, 212, 28-38.	4.0	61
204	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 2015, 63, 573-580.	3.7	46
205	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV, 2015, 2, e127-e136.	4.7	180
206	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. Journal of Infectious Diseases, 2015, 212, 578-584.	4.0	20
207	Performance of the 47-Kilodalton Membrane Protein versus DNA Polymerase I Genes for Detection of Treponema pallidum by PCR in Ulcers. Journal of Clinical Microbiology, 2015, 53, 976-980.	3.9	15
208	Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. Aids, 2015, 29, 231-238.	2.2	30
209	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. Aids, 2015, 29, 221-229.	2.2	208
210	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterology, 2015, 15, 79.	2.0	18
211	Use of <i>Treponema pallidum</i> PCR in Testing of Ulcers for Diagnosis of Primary Syphilis. Emerging Infectious Diseases, 2015, 21, 127-129.	4.3	46
212	Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 2015, 16, 3-14.	2.2	12
213	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv257.	3.0	6
214	Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study. HIV Medicine, 2015, 16, 319-325.	2.2	29
215	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. PLoS ONE, 2015, 10, e0133879.	2.5	5
216	Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. Swiss Medical Weekly, 2015, 145, w14206.	1.6	10

#	ARTICLE	IF	CITATIONS
217	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIV-HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2014, 19, 149-159.	1.0	11
218	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014, 17, 19490.	3.0	41
219	Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. <i>Journal of the International AIDS Society</i> , 2014, 17, 19622.	3.0	3
220	AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be. <i>Journal of the International AIDS Society</i> , 2014, 17, 19621.	3.0	4
221	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.9	61
222	Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model. <i>PLoS Pathogens</i> , 2014, 10, e1004156.	4.7	70
223	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	1.9	64
224	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. <i>Aids</i> , 2014, 28, 2231-2239.	2.2	20
225	HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment. <i>Aids</i> , 2014, 28, 1840-1844.	2.2	3
226	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy. <i>Aids</i> , 2014, 28, 1769-1781.	2.2	48
227	Treatment-Naïve Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	5.8	75
228	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	1.9	36
229	The IFNL3/4 17G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. <i>Aids</i> , 2014, 28, 1885-1889.	2.2	37
230	The rate of recovery in renal function when patients with <sc>HIV</sc> infection discontinue treatment with tenofovir. <i>HIV Medicine</i> , 2014, 15, 505-510.	2.2	8
231	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	3.0	31
232	Seroprevalence of Hepatitis E Virus in Domestic Pigs and Wild Boars in Switzerland. <i>Zoonoses and Public Health</i> , 2014, 61, 537-544.	2.2	38
233	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	4.0	16
234	Patients with AIDS â€œdefining cancers are not universally screened for HIV : a 10-year retrospective analysis of HIV â€œtesting practices in a S wiss university hospital. <i>HIV Medicine</i> , 2014, 15, 631-634.	2.2	15



#	ARTICLE	IF	CITATIONS
235	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. <i>American Journal of Epidemiology</i> , 2014, 179, 1514-1525.	3.4	25
236	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
237	Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 716-724.	2.1	14
238	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	5.8	136
239	Virologic and Immunologic Responses in Treatment-Naïve Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. <i>HIV Clinical Trials</i> , 2014, 15, 92-103.	2.0	4
240	Asking about adherence “from flipping the coin to strong evidence. <i>Swiss Medical Weekly</i> , 2014, 144, w14016.	1.6	8
241	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	1.0	31
242	The Prevalence of Erectile Dysfunction and Its Association with Antiretroviral Therapy in HIV-Infected Men: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2013, 18, 337-344.	1.0	24
243	Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2013, 14, 195-207.	2.2	329
244	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	3.2	22
245	Risk of Cardiovascular Events and Blood Pressure Control in Hypertensive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 396-404.	2.1	49
246	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <i>Aids</i> , 2013, 27, 203-210.	2.2	23
247	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2013, 208, 1454-1458.	4.0	67
248	Rivastigmine for HIV-associated neurocognitive disorders. <i>Neurology</i> , 2013, 80, 553-560.	1.1	32
249	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. <i>PLoS Computational Biology</i> , 2013, 9, e1003203.	3.2	19
250	Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003423.	4.7	25
251	HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. <i>PLoS Genetics</i> , 2013, 9, e1003318.	3.5	78
252	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 178, 877-884.	3.4	116



#	ARTICLE	IF	CITATIONS
253	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1102-1112.	4.0	35
254	Adherence to Antiretroviral Treatment Decreases During Postpartum Compared to Pregnancy: A Longitudinal Electronic Monitoring Study. <i>AIDS Patient Care and STDs</i> , 2013, 27, 208-210.	2.5	17
255	Suboptimal access to primary healthcare among street-based sex workers in southwest Switzerland. <i>Postgraduate Medical Journal</i> , 2013, 89, 371-375.	1.8	20
256	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	1.6	45
257	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 28-35.	2.1	86
258	Impact of Recommendation Updates in Well-Controlled Patients on Nonrecommended Antiretroviral Therapies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 180-189.	2.1	3
259	A light in the cognitive fog?. <i>Antiviral Therapy</i> , 2013, 18, 149-151.	1.0	2
260	Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. <i>PLoS ONE</i> , 2013, 8, e72547.	2.5	19
261	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	2.2	70
262	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 9-18.	1.5	25
263	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. <i>PLoS ONE</i> , 2013, 8, e62980.	2.5	51
264	Awareness of HIV Testing Guidelines Is Low among Swiss Emergency Doctors: A Survey of Five Teaching Hospitals in French-Speaking Switzerland. <i>PLoS ONE</i> , 2013, 8, e72812.	2.5	10
265	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013, 8, e77691.	2.5	49
266	A cross-sectional survey of attitudes to HIV risk and rapid HIV testing among clients of sex workers in Switzerland. <i>Sexually Transmitted Infections</i> , 2012, 88, 462-464.	1.9	18
267	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	3.2	39
268	Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. <i>British Journal of Cancer</i> , 2012, 106, 447-452.	6.4	73
269	Role of retroviral restriction factors in the interferon- $\gamma$ -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3035-3040.	7.1	129
270	Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY) <sub>n</sub> in gp120 of HIV Type1. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 493-504.	1.1	0

#	ARTICLE	IF	CITATIONS
271	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	3.8	31
272	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-naïve Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	5.8	32
273	Longer Term Clinical and Virological Outcome of Sub-Saharan African Participants on Antiretroviral Treatment in the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 79-85.	2.1	29
274	Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 265-269.	2.1	22
275	Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 135-142.	2.1	23
276	Long-Term Close Follow-up of Chorioretinal Lesions in Presumed Ocular Tuberculosis. European Journal of Ophthalmology, 2012, 22, 195-202.	1.3	11
277	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012, 26, 567-575.	2.2	68
278	Multiclass Primary Antiretroviral Drug Resistance in a Patient Presenting HIV-1/2 Dual Infection. Antiviral Therapy, 2012, 17, 593-594.	1.0	3
279	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically infected, ART-treated HIV patients. European Journal of Immunology, 2012, 42, 3038-3048.	2.9	30
280	Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen. Journal of Infection, 2012, 65, 157-164.	3.3	22
281	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. Cytokine, 2012, 60, 338-340.	3.2	21
282	Tuberculosis in HIV-Negative and HIV-Infected Patients in a Low-Incidence Country: Clinical Characteristics and Treatment Outcomes. PLoS ONE, 2012, 7, e34186.	2.5	13
283	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.	2.5	15
284	HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital. PLoS ONE, 2012, 7, e39299.	2.5	14
285	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.	2.5	16
286	Characteristics of HIV patients referred to a medication adherence program in Switzerland. International Journal of Clinical Pharmacy, 2012, 34, 426-431.	2.1	6
287	Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study <sup>*</sup> . HIV Medicine, 2012, 13, 118-126.	2.2	32
288	An analysis of patients' understanding of "routine" preoperative blood tests and HIV screening. Is no news really good news?. HIV Medicine, 2012, 13, 439-443.	2.2	15

#	ARTICLE	IF	CITATIONS
289	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. <i>AIDS and Behavior</i> , 2012, 16, 245-255.	2.7	20
290	Higher Memory Responses in HIV-Infected and Kidney Transplanted Patients than in Healthy Subjects following Priming with the Pandemic Vaccine. <i>PLoS ONE</i> , 2012, 7, e40428.	2.5	11
291	An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 550-561.	1.2	60
292	Hepatitis E Virus Seroprevalence among Blood Donors in Southwest Switzerland. <i>PLoS ONE</i> , 2011, 6, e21150.	2.5	88
293	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 24-31.	2.1	23
294	HIV-associated neurocognitive disorders: a changing pattern. <i>Future Neurology</i> , 2011, 6, 81-95.	0.5	4
295	A randomized crossover study to compare efavirenz and etravirine treatment. <i>Aids</i> , 2011, 25, 57-63.	2.2	34
296	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	1.0	77
297	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. <i>Antiviral Therapy</i> , 2011, 16, 189-197.	1.0	38
298	Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study*. <i>HIV Medicine</i> , 2011, 12, 279-288.	2.2	17
299	Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2011, 12, 299-307.	2.2	13
300	Clinical relevance of cytomegalovirus viraemia*,â€. <i>HIV Medicine</i> , 2011, 12, 394-402.	2.2	29
301	Dominant TNF-Î±+ Mycobacterium tuberculosisâ€“specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011, 17, 372-376.	30.7	380
302	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TBâ„¢) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. <i>BMC Infectious Diseases</i> , 2011, 11, 319.	2.9	28
303	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. <i>Journal of Translational Medicine</i> , 2011, 9, 14.	4.4	8
304	Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 525-533.	1.1	8
305	Outbreak of Mycobacterium haemophilum Infections after Permanent Makeup of the Eyebrows. <i>Clinical Infectious Diseases</i> , 2011, 52, 488-491.	5.8	53
306	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1573-1581.	3.0	25

#	ARTICLE	IF	CITATIONS
307	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipodystrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	4.0	11
308	Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 248-256.	5.8	114
309	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	4.0	74
310	A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). <i>Aids</i> , 2011, 25, 1481-1487.	2.2	55
311	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	3.0	131
312	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	5.8	525
313	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	5.8	53
314	Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving Nevirapine or Efavirenz. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 264-268.	2.1	6
315	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	4.0	89
316	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	5.8	127
317	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	2.5	46
318	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. <i>Emerging Infectious Diseases</i> , 2011, 17, 1074-1078.	4.3	123
319	Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. <i>Aids</i> , 2010, 24, 1907-1916.	2.2	49
320	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	1.0	172
321	Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. <i>Aids</i> , 2010, 24, 1243-1250.	2.2	592
322	Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 31-40.	1.0	12
323	Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.	3.8	127
324	Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART. <i>Annals of Hematology</i> , 2010, 89, 425-426.	1.8	8

#	ARTICLE	IF	CITATIONS
325	Periurethral abscess complicating gonococcal urethritis: case report and literature review. <i>Infection</i> , 2010, 38, 497-500.	4.7	8
326	Antiretroviral adherence program in HIV patients: a feasibility study in the Swiss HIV Cohort Study. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 776-786.	1.4	22
327	Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. <i>HIV Medicine</i> , 2010, 11, 584-592.	2.2	40
328	Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. <i>British Journal of Cancer</i> , 2010, 103, 416-422.	6.4	276
329	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.	1.5	104
330	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 197-203.	2.1	91
331	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. <i>Aids</i> , 2010, 24, 2347-2354.	2.2	101
332	Frequency and Determinants of Unprotected Sex among HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.	5.8	83
333	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	5.8	26
334	A 48-Year-Old Man with Laryngeal Mass and Vocal Cord Palsy. <i>Clinical Infectious Diseases</i> , 2010, 50, 1680-1681.	5.8	1
335	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	4.0	172
336	HIV-1 elite controllers: Beware of super-infections. <i>Journal of Clinical Virology</i> , 2010, 47, 376-378.	3.1	32
337	HIV-1 Drug Resistance Transmission Networks in Southwest Switzerland. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1233-1238.	1.1	18
338	Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1239-1246.	1.1	4
339	Lower limb high arterial flow induced by tenofovir and emtricitabine treatment. <i>Antiviral Therapy</i> , 2009, 14, 865-867.	1.0	4
340	Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2009, 48, 1459-1466.	5.8	123
341	Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naïve and -Adherent Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 239-247.	5.8	188
342	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	5.8	43

#	ARTICLE	IF	CITATIONS
343	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
344	Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 659-666.	5.8	119
345	High Prevalence of Anorectal Chlamydial Infection in HIV-Infected Men Who Have Sex with Men in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 49, 1532-1535.	5.8	27
346	Comparison of HIV-infected patients' characteristics, healthcare resources use and cost between native and migrant patients. <i>International Journal of Public Health</i> , 2009, 54, 5-10.	2.6	17
347	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 485-494.	4.7	113
348	Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2009, 10, 12-18.	2.2	57
349	Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2009, 10, 407-416.	2.2	70
350	How reliable is an undetectable viral load?. <i>HIV Medicine</i> , 2009, 10, 470-476.	2.2	9
351	A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	2.3	101
352	Histoplasma capsulatum var. duboisii infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 85-89.	1.8	16
353	Prolonged seroconversion in an elite controller of HIV-1 infection. <i>Journal of Clinical Virology</i> , 2009, 46, 371-373.	3.1	5
354	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 300-309.	1.5	133
355	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	1.0	9
356	Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2009, 10, 207-214.	2.0	3
357	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	2.5	18
358	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009, 14, 349-357.	1.0	45
359	Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	2.9	138
360	Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>British Journal of Cancer</i> , 2008, 99, 800-804.	6.4	135



#	ARTICLE	IF	CITATIONS
361	Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 2008, 9, 397-405.	2.2	104
362	Androgen and gonadotropin patterns differ in HIV-infected men who develop lipodystrophy during antiretroviral therapy: a case-control study. HIV Medicine, 2008, 9, 427-432.	2.2	13
363	Severe atherosclerotic aortoiliac occlusive disease in a young HIV-infected patient. Lancet Infectious Diseases, The, 2008, 8, 582.	9.1	0
364	Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart, 2008, 95, 385-390.	2.9	38
365	Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. Aids, 2008, 22, 1019-1028.	2.2	64
366	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2008, 197, 1685-1694.	4.0	95
367	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. Clinical Infectious Diseases, 2008, 46, 1299-1309.	5.8	35
368	High Prevalence of Peripheral Arterial Disease in HIV-Infected Persons. Clinical Infectious Diseases, 2008, 46, 761-767.	5.8	105
369	CD4 <sup>+</sup> T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 47, 1093-1101.	5.8	46
370	Hemophagocytic syndrome after highly active antiretroviral therapy initiation: a life-threatening event related to immune restoration inflammatory syndrome?. Aids, 2008, 22, 549-551.	2.2	11
371	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. Therapeutic Drug Monitoring, 2008, 30, 511-522.	2.0	47
372	Low Current and Nadir CD4 <sup>+</sup> T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 455-460.	1.0	15
373	Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1077-1082.	1.0	71
374	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1019-1028.	1.0	29
375	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. Antiviral Therapy, 2008, 13, 77-86.	1.0	100
376	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2007, 45, 111-119.	5.8	233
377	Ecological Study of the Predictors of Successful Management of Dyslipidemia in HIV-Infected Patients on ART: the Swiss HIV Cohort Study. HIV Clinical Trials, 2007, 8, 77-85.	2.0	8
378	Reducing Tuberculosis Incidence by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy in an Area of Low Tuberculosis Transmission. Clinical Infectious Diseases, 2007, 44, 94-102.	5.8	114



#	ARTICLE	IF	CITATIONS
379	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	2.2	7
380	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 557-566.	4.7	240
381	HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. <i>Journal of Internal Medicine</i> , 2007, 261, 255-267.	6.0	16
382	Neuromyelitis optica following CMV primo-infection. <i>Journal of Internal Medicine</i> , 2007, 261, 500-503.	6.0	32
383	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 261-266.	1.0	69
384	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 931-940.	1.0	26
385	CD4 <sup>+</sup> T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 889-898.	1.0	27
386	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 1165-1174.	1.0	109
387	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-1164.	1.0	35
388	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. <i>Lancet</i> , 2006, 368, 459-465.	13.7	233
389	Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 385-392.	2.1	156
390	Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. <i>Clinical Microbiology and Infection</i> , 2006, 12, 666-671.	6.0	19
391	Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2006, 7, 404-410.	2.2	130
392	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	3.2	82
393	Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study. <i>British Journal of Cancer</i> , 2006, 95, 1598-1602.	6.4	27
394	Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	6
395	HIV and solid organ transplantation: the Swiss experience. <i>Swiss Medical Weekly</i> , 2006, 136, 194-6.	1.6	7
396	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. <i>Antiviral Therapy</i> , 2006, 11, 787-796.	1.0	63

#	ARTICLE	IF	CITATIONS
397	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	28
398	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	2.2	29
399	Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. <i>Aids</i> , 2005, 19, 1837-1842.	2.2	15
400	Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy. <i>HIV Clinical Trials</i> , 2005, 6, 92-102.	2.0	13
401	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	5.8	285
402	Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 95-101.	1.8	96
403	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	1.0	95
404	HIV-1 co/super-infection in intravenous drug users. <i>Aids</i> , 2004, 18, 1413-1421.	2.2	62
405	Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. <i>Aids</i> , 2004, 18, 356-358.	2.2	10
406	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004, 18, 1707-1714.	2.2	31
407	Long-term safety of discontinuation of secondary prophylaxis against <i>Pneumocystis pneumonia</i> . <i>Aids</i> , 2004, 18, 2047-2053.	2.2	12
408	Gynecomastia and potent antiretroviral therapy. <i>Aids</i> , 2004, 18, 1347-1349.	2.2	14
409	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	1.0	11
410	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. <i>Aids</i> , 2003, 17, F33-F37.	2.2	78
411	Disseminated histoplasmosis in Switzerland: an unexpected cause of septic shock and multiple organ dysfunction. <i>Intensive Care Medicine</i> , 2002, 28, 1501-1502.	8.2	5
412	Evaluation of MRSA-Screen, a Simple Anti-PBP 2a Slide Latex Agglutination Kit, for Rapid Detection of Methicillin Resistance in <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 1999, 37, 1591-1594.	3.9	111
413	Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors. <i>F1000Research</i> , 0, 8, 1400.	1.6	1
414	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLA™HIV Trial). <i>Frontiers in Virology</i> , 0, 2, .	1.4	0